123I-metaiodobenzylguanidine scans in phaeochromocytoma diagnosis: Current clinical practice and relationship to biochemical screening

International Journal of Clinical Practice

Volumn 53, Issue 6, 1999, Pages

  Tormey, W P ^a   Keeling, F ^a   Lee, M J ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; CATECHOLAMINE; METADRENALIN; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOCHEMISTRY; CATECHOLAMINE URINE LEVEL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RECURRENT DISEASE; SCINTISCANNING; SCREENING TEST; TEACHING HOSPITAL; TUMOR LOCALIZATION; ADRENAL TUMOR; BLOOD; CLINICAL PRACTICE; LABORATORY DIAGNOSIS; MIDDLE AGED;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; PHYSICIAN'S PRACTICE PATTERNS; RADIOPHARMACEUTICALS; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 0033183494     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Stein PP, Black HR. A simplified approach to pheochromocytoma: a review of the literature and report on one institution's experience. Medicine 1990; 70: 46-66.
2. Tormey WP, FitzGerald RJ. Lack of uniformity in the clinical approach to the interpretation of urinary catecholamines and their metabolites. Ir J Med Sci 1995; 164: 146-150.
3. 131I-MIBG era. World J Surg 1988; 12: 546-551.
4. Chatal JF, Charbonnel B. Comparison of iodobenzylguanidine imaging with computed tomography in locating pheochromocytoma. J Clin Endocrinol Metab 1985; 61: 769-772.
5. Maurea S, Cuocolo A, Reynolds JC et al. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 1993; 34: 173-179.
6. Shapiro B, Copp JE, Sisson JC et al. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 1985; 26: 576-585.
7. Plouin P-F, Degoulet P, Tugaye A et al. Le depistage du pheochromocytome: chez quels hypertendus? Etude semiologique chez 2585 hypertendus dont 11 ayant un pheochromocytome. Nouv Presse Med 1981; 10: 869-872.
8. Sclafani LM, Woodruff JM, Brennan MF. Extraadrenal retroperitoneal paragangliomas: natural history and response to treatment. Surgery 1990; 108: 1124-1130.
9. Melicow MM. One hundred cases of pheochromocytoma (107 tumors) at the Columbia Presbyterian Medical Center, 1926-1976. Cancer 1977; 40: 1987-2004.
10. O'Neill G, Tormey WP, Farrell MA et al. Phaeochromocytoma and lethal lactic acidaemia. Ir Med J 1993; 86: 221.
11. 131I]iodobenzylguanidine. J Nucl Med 1980; 21: 349-353.
12. Sisson JC, Wieland DM, Sherman P et al. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987; 28: 1620-1624.
13. FitzGibbon M, FitzGerald RJ, Tormey WP et al. Reference values for urinary HMMA, HVA, noradrenaline, adrenaline and dopamine excretion in children using random urine samples and HPLC with electrochemical detection. Ann Clin Biochem 1992; 29: 400-404.
14. Davidson DF, FitzPatrick J. A simple, optimised and rapid assay for urinary free catecholamines by HPLC with electrochemical detection. Ann Clin Biochem 1985; 22: 297-303.
15. Neumann HPH, Berger DP, Sigmund G et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and Von Hippel-Lindau disease. N Engl J Med 1993; 329: 1531-1538.
16. St John Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma: review of a 50-year autopsy series. Mayo Clin Proc 1981; 56: 354-360.
17. Stenstrom G, Svardsudd K. Pheochromocytoma in Sweden 1958-1981. Acta Med Scand 1986; 220: 225-232.
18. Varghese JC, Hahn PF, Papanicolaou N et al. MR differentiation of phaeochromocytoma from other adrenal lesions based on qualitative analysis of T2 relaxation times. Clin Radiol 1997; 52: 603-606.
19. Davis SD. CT evaluation for pulmonary metastases in patients with extrathoracic malignancy. Radiology 1991; 180: 1-12.
20. Webb WR, Sostman HD. MR imaging of thoracic disease: clinical uses. Radiology 1992; 182: 6221-6630.
21. Chatal J-F. Can we agree on the best imaging procedure(s) for localization of pheochromocytomas? J Nucl Med 1993; 33: 180-181.
22. Lynn MD, Shapiro B, Sisson JC et al. Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Radiology 1985; 155: 789-792.
23. Kopf D, Bockisch A, Steinert H et al. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol 1997; 46: 39-44.
24. Juan D. Pharmacologic agents in the management of pheochromocytoma. South Med J 1982; 75: 211-216.
25. Lucon AM, Pereira MAA, Mendonca BB et al. Pheochromocytoma: study of 50 cases. J Urol 1997; 157: 1208-1212.
26. Loh KC, Shlossberg AH, Abbott EC et al. Phaeochromocytoma: a ten year survey. Q J Med 1997; 90: 51-60.
27. Bravo EL. Evolving concepts in the pathophysiology, diagnosis and treatment of pheochromocytoma. Endoc Rev 1994; 15: 356-368.
28. Heron E, Chatellier G, Billaud E et al. The urinary metanephrine-to-creatinine ratio for the diagnosis of pheochromocytoma. Ann Intern Med 1996; 125: 300-303.
29. Graham PE, Smythe GA, Edwards GA, Lazarus L. Laboratory diagnosis of phaeochromocytoma: which analytes should we measure? Ann Clin Biochem 1993; 30: 129-134.
30. Wolthers BG, Kema IP, Volmer M et al. Evaluation of urinary metanephrine and normetanephrine enzyme immunoassay (ELISA) kits by comparison with isotope dilution mass spectrometry. Clin Chem 1997; 43: 114-120.